Theriva Biologics (SYN) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 50 253 sessions, October 12, 2021 to October 12, 2022
- Largest daily move
- +37.6% close of March 17, 2022
- 1-year change
- -77% closing prices, October 12, 2021 to October 12, 2022
- 1-month change
- -28.2% closing prices, September 12, 2022 to October 12, 2022
Company Description
Theriva Biologics (Nasdaq: SYN) is classified in the biotechnology industry within the Healthcare sector.
SYN has declined 77.0% over the past year. The last closing price was $1.02.
This page collects what Stock Titan holds for SYN, including price data and latest news.
Stock Performance
Theriva Biologics (SYN) closed at $1.02 on October 12, 2022. Over the past 12 months, the price has lost 77.0%.
SYN Metrics & Rankings
Price returns through October 12, 2022. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Theriva Biologics has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 5 with negative movement. Key topics include clinical trial, earnings, conferences, earnings date, private placement. View all SYN news →
SEC Filings
SYN Company Profile & Sector Positioning
Theriva Biologics (SYN) operates in the Biotechnology industry within the broader Healthcare sector.
Investors comparing SYN often look at related companies in the same sector, including Edesa Biotech, Inc. (EDSA), Cellectar Biosciences INC NEW (CLRB), Tharimmune, Inc. (THAR), MetaVia Inc. (MTVA), and Longeveron Inc. (LGVN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SYN's relative position within its industry.